Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS
Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019. MacroGenics' trial compared its margetuximab candida
Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based on a biomarker (gBRCA mt) in first-line metastatic disease.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
